The role of rasagiline in the treatment of Parkinson’s disease
Julie Leegwater-Kim1, Elena Bortan21Tufts University School of Medicine and Department of Neurology, Lahey Clinic, Burlington, MA, USA; 2Department of Neurology, Lahey Clinic, Burlington, MA, USAAbstract: Parkinson’s disease (PD) is the second most common neurodegenerative disorder, affect...
Guardado en:
| Autores principales: | , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2010
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/8a3d0ef37dd64bfa898515d373301e9e |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:8a3d0ef37dd64bfa898515d373301e9e |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:8a3d0ef37dd64bfa898515d373301e9e2021-12-02T03:15:31ZThe role of rasagiline in the treatment of Parkinson’s disease1178-1998https://doaj.org/article/8a3d0ef37dd64bfa898515d373301e9e2010-05-01T00:00:00Zhttps://www.dovepress.com/the-role-of-rasagiline-in-the-treatment-of-parkinsonrsquos-disease-peer-reviewed-article-CIAhttps://doaj.org/toc/1178-1998Julie Leegwater-Kim1, Elena Bortan21Tufts University School of Medicine and Department of Neurology, Lahey Clinic, Burlington, MA, USA; 2Department of Neurology, Lahey Clinic, Burlington, MA, USAAbstract: Parkinson’s disease (PD) is the second most common neurodegenerative disorder, affecting 1% to 2% of people older than 60 years. Treatment of PD consists of symptomatic therapies while neuroprotective strategies have remained elusive. Rasagiline is a novel, potent, and irreversible monoamine oxidase type B (MAO-B) inhibitor which has been approved for treatment of PD. Rasagiline inhibits MAO-B more potently than selegiline and has the advantage of once-daily dosing. In several large, randomized, placebo-controlled trials, rasagiline has demonstrated efficacy as monotherapy in early PD and as adjunctive therapy in advanced PD. In addition, rasagiline has been shown to have neuroprotective effects in in vitro and in vivo studies. The recently completed delayed-start ADAGIO (Attenuation of Disease Progression with Azilect Given Once-daily) trial suggests a potential disease-modifying effect for rasagiline 1 mg/day, though the clinical import of this finding has yet to be established.Keywords: rasagiline, monoamine oxidase inhibitor, Parkinson’s diseaseJulie Leegwater-KimElena BortanDove Medical Pressarticlerasagilinemonoamine oxidase inhibitorParkinson's diseaseneuroprotectionGeriatricsRC952-954.6ENClinical Interventions in Aging, Vol Volume 5, Pp 149-156 (2010) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
rasagiline monoamine oxidase inhibitor Parkinson's disease neuroprotection Geriatrics RC952-954.6 |
| spellingShingle |
rasagiline monoamine oxidase inhibitor Parkinson's disease neuroprotection Geriatrics RC952-954.6 Julie Leegwater-Kim Elena Bortan The role of rasagiline in the treatment of Parkinson’s disease |
| description |
Julie Leegwater-Kim1, Elena Bortan21Tufts University School of Medicine and Department of Neurology, Lahey Clinic, Burlington, MA, USA; 2Department of Neurology, Lahey Clinic, Burlington, MA, USAAbstract: Parkinson’s disease (PD) is the second most common neurodegenerative disorder, affecting 1% to 2% of people older than 60 years. Treatment of PD consists of symptomatic therapies while neuroprotective strategies have remained elusive. Rasagiline is a novel, potent, and irreversible monoamine oxidase type B (MAO-B) inhibitor which has been approved for treatment of PD. Rasagiline inhibits MAO-B more potently than selegiline and has the advantage of once-daily dosing. In several large, randomized, placebo-controlled trials, rasagiline has demonstrated efficacy as monotherapy in early PD and as adjunctive therapy in advanced PD. In addition, rasagiline has been shown to have neuroprotective effects in in vitro and in vivo studies. The recently completed delayed-start ADAGIO (Attenuation of Disease Progression with Azilect Given Once-daily) trial suggests a potential disease-modifying effect for rasagiline 1 mg/day, though the clinical import of this finding has yet to be established.Keywords: rasagiline, monoamine oxidase inhibitor, Parkinson’s disease |
| format |
article |
| author |
Julie Leegwater-Kim Elena Bortan |
| author_facet |
Julie Leegwater-Kim Elena Bortan |
| author_sort |
Julie Leegwater-Kim |
| title |
The role of rasagiline in the treatment of Parkinson’s disease |
| title_short |
The role of rasagiline in the treatment of Parkinson’s disease |
| title_full |
The role of rasagiline in the treatment of Parkinson’s disease |
| title_fullStr |
The role of rasagiline in the treatment of Parkinson’s disease |
| title_full_unstemmed |
The role of rasagiline in the treatment of Parkinson’s disease |
| title_sort |
role of rasagiline in the treatment of parkinson’s disease |
| publisher |
Dove Medical Press |
| publishDate |
2010 |
| url |
https://doaj.org/article/8a3d0ef37dd64bfa898515d373301e9e |
| work_keys_str_mv |
AT julieleegwaterkim theroleofrasagilineinthetreatmentofparkinsonrsquosdisease AT elenabortan theroleofrasagilineinthetreatmentofparkinsonrsquosdisease AT julieleegwaterkim roleofrasagilineinthetreatmentofparkinsonrsquosdisease AT elenabortan roleofrasagilineinthetreatmentofparkinsonrsquosdisease |
| _version_ |
1718401869569589248 |